Percheron Therapeutics Announces Terminated of ATL1102 Study for DMD

Percheron Therapeutics says it will abandon its lead drug candidate altogether, following December’s Duchenne muscular dystrophy trial flop. Percheron Therapeutics announces terminated of ATL1102 study for DMD.

“One way or other, we don’t think ATL-1102 can remain the centerpiece of the story put forward to investors,” Garner told investors in a webinar this morning.

In summary, the trial failed to detect any meaningful difference between the boys actively treated with ATL-1102, compared with the placebo cohort. [Read More: Percheron Disappointed in Avicursen (ATL1102) Study For Duchenne (DMD)]

Learn More: Cures of Duchenne (List of All Researches)

- Follow Us -
DMDWarrioR Instagram
SourceNTNEWS

Disclaimer: No content on this site should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

LEAVE A REPLY

Please enter your comment!
Please enter your name here


Hot Topics

Related Articles